Sanofi annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi Revenue Growth & History (SAN)
Sanofi reported €43.63B in revenue for fiscal 2025, an increase of 6.20% from the previous fiscal year.
View full Sanofi company overviewSanofi annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €43.63B | €2.54B | +6.20% |
| 2024 | 2024-12-31 | €41.08B | €3.26B | +8.63% |
| 2023 | 2023-12-31 | €37.82B | €166.0M | +0.44% |
| 2022 | 2022-12-31 | €37.65B | −€110.0M | −0.29% |
| 2021 | 2021-12-31 | €37.76B | €1.72B | +4.77% |
| 2020 | 2020-12-31 | €36.04B | −€85.0M | −0.24% |
| 2019 | 2019-12-31 | €36.13B | €1.66B | +4.83% |
| 2018 | 2018-12-31 | €34.46B | −€609.0M | −1.74% |
| 2017 | 2017-12-31 | €35.07B | €1.26B | +3.74% |
| 2016 | 2016-12-31 | €33.81B | −€251.0M | −0.74% |
| 2015 | 2015-12-31 | €34.06B | — | — |
Sanofi quarterly revenue
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €12.30B | €1.56B | +14.58% |
| Q1 2026 | 2026-03-31 | €11.24B | — | — |
| Q4 2025 | 2025-12-31 | €12.21B | — | — |
| Q3 2025 | 2025-09-30 | €13.17B | — | — |
| Q2 2025 | 2025-06-30 | €10.73B | — | — |
Sanofi revenue growth trends
Over the last five reported fiscal years, revenue grew from €36.04B to €43.63B, a compound annual growth rate of 3.89%. Sanofi's latest reported quarter, Q2 2026, generated €12.30B in revenue, an increase of 14.58% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Sanofi source filings ↗Community posts
Sanofi raises annual outlook as Dupixent drives double-digit sales growth
Sanofi ($SAN-EURONEXT) increased its 2026 outlook to low-teens sales growth and mid-teens growth in business earnings per share, both at constant exchange rates. Third-quarter 2026 sales reached €14.44 billion, increasing 14.3% on that basi ...
